102 related articles for article (PubMed ID: 30355949)
1. Combined Effect of IL-12Rβ2 and IL-23R Expression on Prognosis of Patients with Laryngeal Cancer.
Tao Y; Tao T; Gross N; Peng X; Li Y; Huang Z; Liu L; Li G; Chen X; Yang J
Cell Physiol Biochem; 2018; 50(3):1041-1054. PubMed ID: 30355949
[TBL] [Abstract][Full Text] [Related]
2. A high ratio of IL-12Rβ2-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer.
Tao Y; Gross N; Liu Y; Zhang L; Li G; Huang Z; Yang J
Oral Oncol; 2017 Nov; 74():148-156. PubMed ID: 29103744
[TBL] [Abstract][Full Text] [Related]
3. IL-23R in laryngeal cancer: a cancer immunoediting process that facilitates tumor cell proliferation and results in cisplatin resistance.
Tao Y; Shen H; Liu Y; Li G; Huang Z; Liu Y
Carcinogenesis; 2021 Feb; 42(1):118-126. PubMed ID: 32526010
[TBL] [Abstract][Full Text] [Related]
4. Deciphering site 3 interactions of interleukin 12 and interleukin 23 with their cognate murine and human receptors.
Esch A; Masiarz A; Mossner S; Moll JM; Grötzinger J; Schröder J; Scheller J; Floss DM
J Biol Chem; 2020 Jul; 295(30):10478-10492. PubMed ID: 32518162
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
6. The co-expression of ERβ2 and IL-12Rβ2 is better prognostic factor in non-small-cell lung cancer progression.
Liu ZG; Lei YY; Li WW; Chen ZG
Med Oncol; 2013; 30(3):592. PubMed ID: 23677568
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
Suzuki K; Kadota K; Sima CS; Nitadori J; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
J Clin Oncol; 2013 Feb; 31(4):490-8. PubMed ID: 23269987
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
9. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.
Parham C; Chirica M; Timans J; Vaisberg E; Travis M; Cheung J; Pflanz S; Zhang R; Singh KP; Vega F; To W; Wagner J; O'Farrell AM; McClanahan T; Zurawski S; Hannum C; Gorman D; Rennick DM; Kastelein RA; de Waal Malefyt R; Moore KW
J Immunol; 2002 Jun; 168(11):5699-708. PubMed ID: 12023369
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis.
Zheng X; Song X; Shao Y; Xu B; Hu W; Zhou Q; Chen L; Zhang D; Wu C; Jiang J
Cell Physiol Biochem; 2018; 45(2):720-732. PubMed ID: 29414812
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum soluble interleukin-23 receptor and related T-helper 17 cell cytokines in non-small cell lung carcinoma.
Liu D; Xing S; Wang W; Huang X; Lin H; Chen Y; Lan K; Chen L; Luo F; Qin S; Liang R; Bai C; Xu J; Liu W
Cancer Sci; 2020 Apr; 111(4):1093-1102. PubMed ID: 32020720
[TBL] [Abstract][Full Text] [Related]
13. Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells.
Airoldi I; Cocco C; Di Carlo E; Disarò S; Ognio E; Basso G; Pistoia V
Cancer Res; 2006 Apr; 66(8):3978-80. PubMed ID: 16618714
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.
Yan X; Jiao SC; Zhang GQ; Guan Y; Wang JL
Cancer Gene Ther; 2017 Feb; 24(2):57-63. PubMed ID: 28084319
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
16. The dichotomous pattern of IL-12r and IL-23R expression elucidates the role of IL-12 and IL-23 in inflammation.
Chognard G; Bellemare L; Pelletier AN; Dominguez-Punaro MC; Beauchamp C; Guyon MJ; Charron G; Morin N; Sivanesan D; Kuchroo V; Xavier R; Michnick SW; Chemtob S; Rioux JD; Lesage S
PLoS One; 2014; 9(2):e89092. PubMed ID: 24586521
[TBL] [Abstract][Full Text] [Related]
17. Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells.
Zhang XY; Zhang HJ; Zhang Y; Fu YJ; He J; Zhu LP; Wang SH; Liu L
Immunogenetics; 2006 Jan; 57(12):934-43. PubMed ID: 16372191
[TBL] [Abstract][Full Text] [Related]
18. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis.
Suzuki M; Iizasa T; Nakajima T; Kubo R; Iyoda A; Hiroshima K; Nakatani Y; Fujisawa T
Ann Surg Oncol; 2007 Sep; 14(9):2636-42. PubMed ID: 17602269
[TBL] [Abstract][Full Text] [Related]
20. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
